FDA Issues Safety Warning for GLP‑1 Obesity Drugs Over Rare Eye Risks

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Here is a roundup of the most important news in biotech and medicine this morning.

The need-to-know this morning

• Beam Therapeutics announced that its CRISPR therapy risto‑cel met the trial’s primary endpoint, providing freedom from severe pain crises for at least 12 months. The company will submit an FDA marketing application by year‑end, though detailed efficacy data have not yet been released.

PepGen shows promising data for muscular dystrophy

PepGen reported that its investigational therapy delivered the most encouraging early results to date for a prevalent form of muscular dystrophy, based on a key efficacy metric.

Source link